Histone deacetylase inhibitors: overview and perspectives
M Dokmanovic, C Clarke, PA Marks - Molecular cancer research, 2007 - AACR
M Dokmanovic, C Clarke, PA Marks
Molecular cancer research, 2007•AACRHistone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a
group of targeted anticancer agents. The first of these new HDACi, vorinostat
(suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for
treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the
11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different
pathways by which HDACi induce transformed cell death. A hypothesis is presented to …
group of targeted anticancer agents. The first of these new HDACi, vorinostat
(suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for
treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the
11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different
pathways by which HDACi induce transformed cell death. A hypothesis is presented to …
Abstract
Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death. (Mol Cancer Res 2007;5(10):981–9)
AACR